Summary
Multiplexed diagnostics are the wild west of medicine. Technology is established, regulation is limited and the number of new biomarkers exploding. First-movers are grabbing biomarker territories, combining independent measurements for efficiency and mining molecules for multivariate panels. All the while demand is high for improving diagnoses and predicting responses to treatment. The challenges, however, are uncertain reimbursement, unclear business models and ever-intensifying competition. On balance, though, the market is prosperous and is estimated to be more than $1.5 billion in 2007 and is projected to grow to more than $6 billion by 2013.
Successful navigation of this difficult terrain requires a detailed understanding of the market. Multiplexed Diagnostics 2008 explains the unmet needs, trends, regulations, competition, technologies and business strategies. The 260-page report includes a survey of more than 200 respondents, a detailed database of more than 135 commercial multiplexed diagnostics and a quantitative market model. In addition, the report comes with one hour of consulting (in the form of a conference call) with the lead author, Steven Bodovitz, Principal of BioPerspectives.
|
